# Find out whether an adult thymus can be made to work again, with an endpoint a clinician would act on

Source: https://onco.cc/ideas/idea-rejuv-thymic-regeneration-in-adults/  
OnCo record `idea-rejuv-thymic-regeneration-in-adults` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Several agents have been tried for thymic recovery after transplant and none is in routine use. The blocker is as much the missing endpoint as the missing drug.

## Summary

After a transplant or intensive therapy, cell counts recover and the range of things the immune system can recognise does not. That deficit is why revaccination programmes exist, why prophylaxis runs for months or years, and why a normal count can reassure falsely. Nothing in routine use shortens it in adults, and the agents tried, including thymic peptides, keratinocyte growth factor, growth hormone and sex steroid blockade, did not produce a treatment.

The honest reading is that this failed partly on biology and partly on design. Thymic output and repertoire diversity are research measures that no regulator has accepted as endpoints, and infection rates need trials larger than this population easily supports. So the field has neither a surrogate it is allowed to use nor a clinical endpoint it can afford.

The work splits in two. The regulatory half is to qualify an immune-recovery measure, by showing in existing transplant cohorts that it predicts infection and vaccine response well enough to be used as a trial endpoint. The biological half is then to test the candidates, old and new, against it. Doing the second without the first is what has already been tried.

## Fields

- Kind: Idea
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; open-problem; immune
- Hypothesis: An intervention that restores thymic output in adults after transplant or intensive therapy will shorten the period of infection susceptibility and improve vaccine responses, and an immune-recovery measure can be qualified well enough to demonstrate that without a trial powered on infections alone.
- Rationale: The transplant facet of this corpus states that there is no randomised evidence that any intervention accelerates thymic recovery in adults, and that the agents trialled for it have not produced a treatment in routine use. Normal cell counts do not mean a normal repertoire, and repertoire measurement is a research tool rather than a clinical test. Everything currently done is substitution: prophylaxis, immunoglobulin replacement and revaccination.
- Proposed test: First, an endpoint-qualification study in existing transplant cohorts linking T-cell receptor excision circles and repertoire diversity to subsequent infections and vaccine responses. Then a randomised trial of a candidate against that qualified endpoint with infection and vaccine response as co-secondaries.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Cordonnier et al., Vaccination of haemopoietic stem cell transplant recipients: ECIL 7 guidelines (Lancet Infectious Diseases 2019): https://doi.org/10.1016/S1473-3099(18)30600-5

## Connected records

- technologies: [B-cell aplasia and low antibodies after CAR-T and bispecifics, and immunoglobulin replacement](https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/), [Rebuilding an immune system: the timeline, lineage by lineage](https://onco.cc/technologies/rejuv-tx-immune-reconstitution-timeline/), [Rebuilding the immune system after treatment](https://onco.cc/technologies/rejuv-frontier-immune-reconstitution/), [Revaccination after transplant: the schedules, and where the UK and the US differ](https://onco.cc/technologies/rejuv-tx-revaccination/)
- roadmaps: [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Nothing in routine use rebuilds an adult's thymus](https://onco.cc/bottlenecks/rejuv-agenda-thymus-does-not-regrow/)

---
JSON: https://onco.cc/api/v1/entities/idea-rejuv-thymic-regeneration-in-adults.json